NeoImmuneTech
Private Company
Total funding raised: $193M
Overview
NeoImmuneTech is a private, pre-revenue biotech developing innovative immunotherapies based on T-cell homeostasis. Its lead asset, NT-I7 (efineptakin alfa), is a long-acting human interleukin-7 (IL-7) designed to expand and enhance T-cell populations, with multiple Phase 1b/2 trials ongoing in oncology and as a vaccine adjuvant. The company's strategy involves advancing NT-I7 both as a monotherapy and in combination with other modalities like checkpoint inhibitors, chemotherapy, and cellular therapies to address significant unmet needs in immuno-oncology and infectious diseases.
Technology Platform
Proprietary long-acting human interleukin-7 (IL-7) hybrid Fc-fusion protein platform designed to modulate T-cell homeostasis, expanding and enhancing T-cell populations, increasing TCR diversity, and inducing stem-cell-like memory properties.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
NeoImmuneTech competes in the T-cell modulation space with companies developing other cytokine therapies (e.g., IL-2, IL-15 agonists) and lymphopenia-reversal agents. Its differentiation lies in NT-I7's specific targeting of IL-7 receptor signaling, which promotes a more diverse and stem-like T-cell profile compared to competitors. Key competitors include Nektar Therapeutics (bempegaldesleukin), ImmunityBio (Anktiva), and smaller biotechs focused on IL-7 biology.